{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:53:53Z","timestamp":1791590033436,"version":"4.3.4"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -altered renal cell carcinoma (RCC) included\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -rearranged and\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -amplified RCC with unclear clinicopathological features and treatment options. Cases of\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -altered RCCs were collected. Fourteen cases showed\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    rearrangement. Five\n                    <jats:italic toggle=\"yes\">MALAT1::TFEB<\/jats:italic>\n                    fusions and one\n                    <jats:italic toggle=\"yes\">ACTB::TFEB<\/jats:italic>\n                    fusion were verified. 8\/14\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -rearranged RCCs showed biphasic \u201cpseudorosette\u201d structure. All\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -rearranged RCC patients were alive without recurrence or metastasis after 3 to 122 months. Fifteen cases showed\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    amplification, including 5 high-level amplifications (&gt;10 copies) and ten low-level amplifications (5 to 10 copies), including 3 cases showing concomitant\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    amplification and rearrangement.\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -amplified RCCs were high-grade, showing papillary, solid, nested, or alveolar arrangements of cells. In addition, 8 cases showed 3 to 4\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    signals were collected, indicating diverse morphologies. PDL1 membranous staining was observed in 9\/10\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -rearranged RCCs, and 11\/13\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -amplified RCCs. Copy number variation analysis revealed specific amplification of chromosome 6p21.1, where\n                    <jats:italic toggle=\"yes\">TFEB, VEGFA6<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">CCND3<\/jats:italic>\n                    were located, in one high- and 2 low-level amplification cases. Four cases with 3 to 4\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    signals did not show specific amplification of this region. Within the follow-up periods of 3 to 64 months, 8\/13\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -amplified RCC cases presented with metastasis, and 3\/13 patients died in the 12th and 24th months. The treatment processes in several cases and the detailed therapeutic course of a\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -amplified case were documented, highlighting the efficacy of PD-1 inhibitors. Our research supported a cutoff of \u22655\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    copies for the diagnosis of\n                    <jats:italic toggle=\"yes\">TFEB<\/jats:italic>\n                    -amplified RCCs, though further studies were needed regarding the threshold. The expression of PDL1 might indicate a potential benefit of PD-1 inhibitors.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002458","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:00:19Z","timestamp":1753351219000},"page":"84-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Clinicopathologic and Molecular Study of TFEB-altered Renal Cell Carcinomas"],"prefix":"10.1097","volume":"50","author":[{"given":"Mengxin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-0723","authenticated-orcid":false,"given":"Ni","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology"},{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urology"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.urology.2020.11.025","article-title":"Clinical and molecular characterization of microphthalmia-associated transcription factor (MITF)-related renal cell carcinoma","volume":"149","author":"Lang","year":"2021","journal-title":"Urology"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0002-9440(10)64680-9","article-title":"A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation","volume":"158","author":"Argani","year":"2001","journal-title":"Am J Pathol"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines11020245","article-title":"TFEB rearranged renal cell carcinoma: pathological and molecular characterization of 10 cases, with novel clinical implications: a single center 10-year experience","volume":"11","author":"Wang","year":"2023","journal-title":"Biomedicines"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00428-024-03968-5","article-title":"A clinicopathological and molecular series of five TFEB-altered renal cell carcinoma (RCC) cases: highlighting an aggressive subset of TFEB-rearranged RCC concomitant with TFEB amplification\/gene copy number gains","volume":"485","author":"Yan","year":"2024","journal-title":"Virchows Arch"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/PAS.0000000000000720","article-title":"TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity","volume":"40","author":"Argani","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/his.14683","article-title":"Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression","volume":"81","author":"Kammerer-Jacquet","year":"2022","journal-title":"Histopathology"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/his.14663","article-title":"Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study","volume":"81","author":"Lobo","year":"2022","journal-title":"Histopathology"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13000-024-01476-3","article-title":"A rare case of TFEB\/6p21\/VEGFA-amplified renal cell carcinoma diagnosed by whole-exome sequencing: clinicopathological and genetic feature report and literature review","volume":"19","author":"Zhang","year":"2024","journal-title":"Diagn Pathol"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1158\/1078-0432.CCR-19-0733","article-title":"TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41379-020-00713-6","article-title":"TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1","volume":"34","author":"Cali\u00f2","year":"2021","journal-title":"Mod Pathol"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"R16-20251215","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"R17-20251215","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/modpathol.2017.24","article-title":"TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management","volume":"30","author":"Gupta","year":"2017","journal-title":"Mod Pathol"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13046-017-0591-4","article-title":"High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods","volume":"36","author":"Su","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/modpathol.2009.58","article-title":"Cathepsin-K immunoreactivity distinguishes MiTF\/TFE family renal translocation carcinomas from other renal carcinomas","volume":"22","author":"Martignoni","year":"2009","journal-title":"Mod Pathol"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/modpathol.2017.99","article-title":"Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays","volume":"31","author":"Skala","year":"2017","journal-title":"Mod Pathol"},{"key":"R21-20251215","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/PAS.0000000000001307","article-title":"TFEB expression profiling in renal cell carcinomas","volume":"43","author":"Gupta","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PAS.0000000000001408","article-title":"Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB tanslocation Renal Cell Carcinomas (RCCs) expanding the genomic spectrum","volume":"44","author":"Xia","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00428-019-02526-8","article-title":"Histological and molecular characterization of TFEB-rearranged renal cell carcinomas","volume":"474","author":"Wyvekens","year":"2019","journal-title":"Virchows Arch"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41379-018-0128-1","article-title":"VEGFA amplification\/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations","volume":"32","author":"Cali\u00f2","year":"2018","journal-title":"Mod Pathol"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1038\/sj.onc.1206443","article-title":"Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival","volume":"22","author":"Widlund","year":"2003","journal-title":"Oncogene"},{"key":"R26-20251215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/PAS.0000000000000776","article-title":"Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis?","volume":"41","author":"Williamson","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R27-20251215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-008-0661-2","article-title":"End-stage kidney disease: gains of chromosomes 7 and 17 and loss of Y chromosome in non-neoplastic tissue","volume":"453","author":"Hes","year":"2008","journal-title":"Virchows Arch"},{"key":"R28-20251215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/exmp.1999.2262","article-title":"Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization","volume":"67","author":"Mark","year":"1999","journal-title":"Exp Mol Pathol"},{"key":"R29-20251215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pathol.2019.11.006","article-title":"Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets","volume":"52","author":"Cali\u00f2","year":"2020","journal-title":"Pathology"},{"key":"R30-20251215","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/modpathol.2017.144","article-title":"t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa\/epithelioid angiomyolipoma","volume":"31","author":"Cali\u00f2","year":"2017","journal-title":"Mod Pathol"},{"key":"R31-20251215","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/his.15304","article-title":"TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape","volume":"85","author":"Agaimy","year":"2024","journal-title":"Histopathology"},{"key":"R32-20251215","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R33-20251215","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/327721a0","article-title":"Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma","volume":"327","author":"Zbar","year":"1987","journal-title":"Nature"},{"key":"R34-20251215","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41379-019-0283-z","article-title":"Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis","volume":"32","author":"Yang","year":"2019","journal-title":"Mod Pathol"},{"key":"R35-20251215","doi-asserted-by":"crossref","first-page":"100303","DOI":"10.1016\/j.modpat.2023.100303","article-title":"AKR1B10 is a new sensitive and specific marker for fumarate hydratase-deficient renal cell carcinoma","volume":"36","author":"Zheng","year":"2023","journal-title":"Mod Pathol"},{"key":"R36-20251215","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/hmg\/ddg178","article-title":"Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution","volume":"12","author":"Kuiper","year":"2003","journal-title":"Hum Mol Genet"},{"key":"R37-20251215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11255-008-9442-8","article-title":"Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma","volume":"41","author":"Pertia","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"R38-20251215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/028418602753669562","article-title":"Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters","volume":"41","author":"Hedberg","year":"2002","journal-title":"Acta Oncol"},{"key":"R39-20251215","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1002\/cncr.26116","article-title":"Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma","volume":"117","author":"Yang","year":"2011","journal-title":"Cancer"},{"key":"R40-20251215","doi-asserted-by":"crossref","first-page":"eabq2630","DOI":"10.1126\/sciimmunol.abq2630","article-title":"Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer","volume":"7","author":"Kwon","year":"2022","journal-title":"Sci Immunol"},{"key":"R41-20251215","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/onc.2013.274","article-title":"Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver","volume":"33","author":"Chang","year":"2014","journal-title":"Oncogene"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:02:33Z","timestamp":1765814553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002458"}},"subtitle":["Tumors With Frequent PDL1 Expression"],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002458","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}